Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) EPS (Basic) (2016 - 2025)

Fate Therapeutics' EPS (Basic) history spans 14 years, with the latest figure at -$0.27 for Q4 2025.

  • For Q4 2025, EPS (Basic) rose 40.0% year-over-year to -$0.27; the TTM value through Dec 2025 reached -$1.15, up 30.3%, while the annual FY2025 figure was -$1.15, 29.88% up from the prior year.
  • EPS (Basic) reached -$0.27 in Q4 2025 per FATE's latest filing, roughly flat from -$0.27 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of -$0.19 in Q1 2023 to a low of -$0.86 in Q3 2022.
  • Average EPS (Basic) over 5 years is -$0.48, with a median of -$0.46 recorded in 2021.
  • Peak YoY movement for EPS (Basic): soared 72.06% in 2023, then plummeted 147.37% in 2024.
  • A 5-year view of EPS (Basic) shows it stood at -$0.72 in 2021, then increased by 19.44% to -$0.58 in 2022, then rose by 22.41% to -$0.45 in 2023, then changed by 0.0% to -$0.45 in 2024, then skyrocketed by 40.0% to -$0.27 in 2025.
  • Per Business Quant, the three most recent readings for FATE's EPS (Basic) are -$0.27 (Q4 2025), -$0.27 (Q3 2025), and -$0.29 (Q2 2025).